HOME >> BIOLOGY >> NEWS
Experimental drug shown to block mutant protein causing blood disease

BOSTON--Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

The researchers also tested the drug, PKC412, in a patient with the hard-to-treat disease, called Myeloproliferative Disease (MPD), and saw her symptoms improve.

PKC412, like the spotlight drug Gleevec, is a highly specific "targeted" drug that disables a switch in cancer cells that has become jammed in the "on" position because of a genetic mutation. The glitch allows a continuous stream of signals to prod blood cells into an uncontrolled frenzy of division and growth. The overproduction of white blood cells in MPD damages organs and generally turns into an acute leukemia that can be fatal.

The report appears in this week's Online Early Edition of the Proceedings of the National Academy of Sciences. Jing Chen, PhD, of Brigham and Women's, and Daniel J. DeAngelo, MD, PhD, of Dana-Farber, are the paper's co-first authors. D. Gary Gilliland, MD, PhD, a Howard Hughes Medical Institute investigator at Brigham and Women's Hospital, and Richard M. Stone, MD, of Dana-Farber are the senior authors. Other authors are from Dana-Farber, Brigham and Women's, Harvard Medical School, Emory University, and Novartis Pharma AG.

"The study shows the potential utility of drugs that block mutant tyrosine kinases, and that these drugs are opening more doors to treating cancers," explains Stone.

Tyrosine kinases are molecules that act as biological switches inside cells, regulating processes including cell division and growth. Abnormal kinases have been discovered to be major culprits in many forms of cancer. Because inhibitor drugs strike the abnormal kinases in cancer cells without harming normal tissue, they are associated with fewer side effects than standard cancer drugs.

In the study, mice with MP
'"/>

Contact: Bill Schaller or Richard Saltus
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
21-Sep-2004


Page: 1 2

Related biology news :

1. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
2. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
3. Experimental Biology 2004 - Translating the Genome
4. Experimental Biology 2004 meets in Washington, D.C. April 17-21
5. Experimental hantavirus vaccine elicits strong antibody response in primates
6. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
7. Experimental Biology 2003 meets in San Diego April 11-15
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental gene switch increases lifespan with no ill effects
10. Experimental therapy stops allergic reactions in mice
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2019)... ... August 29, 2019 , ... Advancements with Ted Danson ... an upcoming episode, which is scheduled to broadcast 1Q/2020. Check local listings for ... cost-effective robotic surgical solutions for the treatment of patients suffering from spinal disorders. ...
(Date:8/27/2019)... ... August 26, 2019 , ... Shoreline Biome , a microbiome research ... hired Bill McKenzie as its CEO and Karen Woodward as its VP of Business ... growing demand for its products and expand the company’s sales worldwide. , Prior to ...
(Date:8/27/2019)... ... 2019 , ... Advancements with Ted Danson will focus on ... broadcast 4Q/2019. Check local listings for more information. , This segment of ... show will highlight how Debiopharm is working to champion the synergy between therapeutic ...
Breaking Biology News(10 mins):
(Date:9/11/2019)... (PRWEB) , ... September 09, 2019 , ... ... life sciences companies and government agencies, announced that its president and CEO Maryann ... of successful business leaders. , The Forbes Council accepted Gallivan based on the ...
(Date:9/8/2019)... YORK (PRWEB) , ... September 04, 2019 , ... ... New York Academy of Sciences announced today the three Winners and six ... outstanding postdoctoral scientists from academic research institutions across New York, New Jersey, and ...
(Date:8/29/2019)... ... August 28, 2019 , ... DuPont Nutrition & Biosciences will ... at the International Baking Industry Expo, September 8 to 11, in booth 5015. ... to cost and waste reduction and from maintaining freshness throughout shelf life to ...
(Date:8/23/2019)... ... ... The EnozoPro® converts ordinary tap water into a sanitizing spray capable of ... including E. Coli, Salmonella, MRSA, Listeria and Legionella. It works as a cleaner, sanitizer ... page at rovingblue.com , ”At Enozo, our mission is to develop solutions to replace ...
Breaking Biology Technology:
Cached News: